BIOCRYST PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $5.00 million as of 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2020-11-06
- 2020-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $5.00M.
- 2020-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $10.00M.
- 2020-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $10.00M.
- 2018-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $3.45M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2020-09-30 | $5.00M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $10.00M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $10.00M 10-Q · filed 2020-05-11 |
| 2018-06-30 | $3.45M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $5.17M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |